Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Kits Designed for ELISA Assay Development

By LabMedica International staff writers
Posted on 23 May 2017
A novel line of kits for the development and optimization of sandwich ELISA assays is now available for biotech and other life science researchers.

The new Innova Biosciences FlexLISA kits are designed for the development and optimization of sandwich ELISA assays to detect the presence of any antigen with a high affinity for any antibody pair in complex samples (such as serum, plasma, or urine).

At the core of the kit is the 30 seconds hands-on time proprietary Lightning-Link conjugation technology for the labeling of the capture and detection antibodies of choice, and a biotin pre-coated 96 well strip-well plate provided either clear or black, depending on the enzymatic substrate.

The kit operates on a rapid one-step protocol that employs pre-blocked microtiter well strips coated with biotin. More...
The FlexLISA assay is run by adding the sample and the antibody mix to the wells, incubating for one hour, washing, and reading the assay plate. FlexLISA is ideal for quick and reliable ELISA assay development, antibody pair screening, and ELISA assay optimization.

The main advantage of this format is that the amount of capture antibody is reduced up to 40-fold, allowing ELISAs to be developed in a cost-effective way using small amounts of commercially available antibodies. The format also allows more than one capture reagent to be used, allowing multiple analytes to be assessed on a single plate.

Anna Sereni, head of research and development at Innova Biosciences, said, “The FlexLISA kit provides researchers with optimum flexibility, and is ideal for quick and reliable ELISA assay development. This is a valuable addition to Innova’s product offering.”


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Laboratory Software
ArtelWare
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers identified SARS-CoV-2 protein fragments within extracellular vesicles in the blood of long COVID patients (Photo courtesy of Shutterstock)

Blood Biomarker Test Could Confirm Long COVID Diagnosis

Long COVID remains a diagnostic challenge, with clinicians currently relying on a collection of symptoms that appear 12 weeks or more after SARS-CoV-2 infection. No blood tests or biomarkers currently... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Insights into sarcomatoid renal cell carcinoma point to broader use of common immunotherapies (Photo courtesy of Salgia NJ et al., Cancer Cell, 2025)

Novel Gene Signature Predicts Immunotherapy Response in Advanced Kidney Cancers

Sarcomatoid renal cell carcinoma (sRCC) is a rare, aggressive form of kidney cancer comprising about 5% of cases and is typically diagnosed at late stages. Resistant to most therapies, it has shown unusually... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.